Primary treatment patterns in women recruited to the Australian Ovarian Cancer Study

被引：0
作者：
J Hung
S Fereday
P Harnett
D Giles
B Gao
N Traficante
G Chenevix-Trench
A Green
P Webb
D Bowtell
A DeFazio
机构：
[1] University of Sydney at Westmead Millennium Institute,Department of Gynaecological Oncology, Westmead Hospital
[2] University of Sydney at Westmead Millennium Institute,Department of Medical Oncology and Palliative Care, Westmead Hospital
[3] University of Sydney at Westmead Millennium Institute,Westmead Institute for Cancer Research, Westmead Hospital
[4] Peter MacCallum Cancer Centre,Department of Biochemistry and Molecular Biology
[5] Queensland Institute of Medical Research,undefined
[6] University of Melbourne,undefined
来源：
Hereditary Cancer in Clinical Practice | / 10卷 / Suppl 2期
关键词：
Ovarian Cancer; Carboplatin; Epithelial Ovarian Cancer; Fallopian Tube; Figo Stage;
D O I：
10.1186/1897-4287-10-S2-A80
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Chemotherapy for ovarian cancer in the Netherlands: a population-based study on treatment patterns and outcomes
    E. Houben
    H. G. M. van Haalen
    W. Sparreboom
    J. A. Overbeek
    N. P. M. Ezendam
    J. M. A. Pijnenborg
    J. L. Severens
    M. P. P. van Herk-Sukel
    Medical Oncology, 2017, 34
  • [32] The roles and limitations of bevacizumab in the treatment of ovarian cancer
    Nakai, Hidekatsu
    Matsumura, Noriomi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1120 - 1126
  • [33] Patterns of Lymphatic Spread in Ovarian Cancer
    Bacalbasa, Nicolae
    Albu, Simona
    Stoica, Claudia
    Brasoveanu, Vladislav
    Balescu, Irina
    PROCEEDINGS OF THE 35TH BALKAN MEDICAL WEEK, 2018, : 396 - 399
  • [34] Primary treatment of advanced ovarian cancer: how does the 'real world' practice?
    Craig, Amaranta D.
    Garcia, Eduardo
    Peters, Pamela N.
    Chen, Lee-may
    Chapman, Jocelyn S.
    FUTURE ONCOLOGY, 2021, 17 (34) : 4687 - 4696
  • [35] Cost Effectiveness of Alternative Strategies for Incorporating Bevacizumab Into the Primary Treatment of Ovarian Cancer
    Barnett, Jason C.
    Secord, Angeles Alvarez
    Cohn, David E.
    Leath, Charles A., III
    Myers, Evan R.
    Havrilesky, Laura J.
    CANCER, 2013, 119 (20) : 3653 - 3661
  • [36] Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer
    Zamboni, William C.
    Combest, Austin J.
    DeLoia, Julie A.
    Edwards, Robert P.
    Bridges, Arlene S.
    Zamboni, Beth A.
    Walko, Christine M.
    Yu, Angela Y. C.
    Krivak, Thomas C.
    Kelley, Joseph L.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) : 1255 - 1262
  • [37] An analysis of ovarian cancer in the Million Women Study
    Neves-E-Castro, Manuel
    GYNECOLOGICAL ENDOCRINOLOGY, 2007, 23 (07) : 410 - 413
  • [38] Should mammographic screening be done in primary ovarian cancer?A case control study in turkish women
    M. Ozguroglu
    B. Avci
    H. Turna
    G. Esen
    B. Arun
    V. Çelik
    S. Serdengeçti
    Medical Oncology, 2004, 21 : 139 - 143
  • [39] Psychosocial factors associated with posttraumatic stress and growth in Australian women with ovarian cancer
    Shand, Lyndel K.
    Brooker, Joanne E.
    Burney, Sue
    Fletcher, Jane
    Ricciardelli, Lina A.
    JOURNAL OF PSYCHOSOCIAL ONCOLOGY, 2018, 36 (04) : 470 - 483
  • [40] First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
    Marchetti, Claudia
    Muzii, Ludovico
    Romito, Alessia
    Panici, Pierluigi Benedetti
    ONCOTARGETS AND THERAPY, 2019, 12 : 1095 - 1103
12345